Teva Pharmaceutical Advances Neuroscience Pipeline With Strong AUSTEDO Growth and New Acquisition

▤ Summary

Teva Pharmaceutical reports strong AUSTEDO growth and broad momentum across its specialty portfolio. The company also closed its acquisition of Emalex Biosciences, which adds ecopipam to its late-stage neuroscience pipeline. Teva continues to advance multiple late-stage programs in neuroscience, immunology, and respiratory disease, including regulatory steps for TEV-749 and ongoing Phase 3 work in asthma and inflammatory diseases. The article also highlights market demand in neuroscience and places Teva’s pipeline progress in the context of broader industry growth.

▦ Linked Companies